By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Pew PatriotsPew PatriotsPew Patriots
Notification Show More
Font ResizerAa
  • Home
  • News
  • Tactical
  • Guns and Gear
  • Prepping & Survival
  • Videos
Reading: FDA approves first twice-yearly injection that prevents HIV infection
Share
Font ResizerAa
Pew PatriotsPew Patriots
  • News
  • Tactical
  • Guns and Gear
  • Prepping & Survival
  • Videos
Search
  • Home
  • News
  • Tactical
  • Guns and Gear
  • Prepping & Survival
  • Videos
Have an existing account? Sign In
Follow US
FDA approves first twice-yearly injection that prevents HIV infection
News

FDA approves first twice-yearly injection that prevents HIV infection

Jimmie Dempsey
Last updated: June 19, 2025 1:06 pm
Jimmie Dempsey Published June 19, 2025
Share
SHARE

NEWYou can now listen to Fox News articles!

The U.S. Food and Drug Administration (FDA) approved a new, twice-yearly shot — the first and only of its kind — to prevent HIV, the creator of the drug, Gilead Sciences, announced on Wednesday.

Sold under the name Yeztugo, the company’s injectable HIV-1 capsid inhibitor (lenacapavir) reduces the risk of sexually acquired HIV in adults and adolescents.

“This is a historic day in the decades-long fight against HIV,” said Daniel O’Day, chairman and CEO of California-based Gilead Sciences, in a press release.

ALZHEIMER’S DISEASE COULD BE PREVENTED BY ANTIVIRAL DRUG ALREADY ON MARKET

The medicine, which only needs to be administered twice a year, has shown “remarkable outcomes in clinical studies,” as Gilead claims it could transform HIV prevention.

The drug is given as an injectable under the skin that the body then slowly absorbs. Individuals must have a negative HIV-1 test prior to starting the treatment.

In large trials last year, the drug was not only nearly 100% effective in its prevention of HIV, but proved superior to once-daily oral medication like Truvada, another drug by Gilead.

A pharmacist holds a vial of lenacapavir

The journal Science named lenacapavir its 2024 “Breakthrough of the Year.”

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Lenacapavir uses a multi-stage approach that distinguishes it from other approved antiviral medications. 

Man at doctor's appointment

“While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle,” states the press release from Gilead.

For more Health articles, visit www.foxnews.com/health

“Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic,” O’Day said in the press release.

The most commonly reported adverse reactions during clinical trials included injection site reactions, headache and nausea, according to the company.

Read the full article here

You Might Also Like

NBC broadcaster Mike Tirico exits Kentucky Derby coverage after falling ill

Mark Carney wins Liberal Party nomination to replace Trudeau as Canada’s next PM

Pope Francis rested well after overcoming setback from respiratory crisis

CBS host defends Trump’s efforts to de-wokify the Smithsonian’s presentation of US history

Masked robbers pull off brazen midday heist at Seattle jewelry store in under two minutes

Share This Article
Facebook Twitter Email Print
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

We Recommend
Abbott clears final redistricting hurdle as Texas Senate passes new Trump-approved map
News

Abbott clears final redistricting hurdle as Texas Senate passes new Trump-approved map

Jimmie Dempsey Jimmie Dempsey August 23, 2025
California school board meeting descends into emotional clash amid trans volleyball player controversy
Viral photos of deer with strange warts follow ‘Frankenstein’ rabbit, squirrel sightings
Lyle Menendez denied parole by California board in Beverly Hills murder case
Virginia leaders condemn racist sign aimed at Lt. Gov. Winsome Earle-Sears over bathroom policy
World War II’s last American ace dies at 103
George Mason University violated Tile VI with ‘unlawful DEI policies,’ Education Department says
News

George Mason University violated Tile VI with ‘unlawful DEI policies,’ Education Department says

Jimmie Dempsey Jimmie Dempsey August 23, 2025
Trump touts tough-on-crime mantra during visit to Guard troops in DC
Tactical

Trump touts tough-on-crime mantra during visit to Guard troops in DC

Jimmie Dempsey Jimmie Dempsey August 23, 2025
Tactile Turns Lemons into Liner Locks with New Skeletonized Rockwall
Guns and Gear

Tactile Turns Lemons into Liner Locks with New Skeletonized Rockwall

Jimmie Dempsey Jimmie Dempsey August 23, 2025
Pew Patriots
  • News
  • Tactical
  • Prepping & Survival
  • Videos
  • Guns and Gear
2024 © Pew Patriots. All Rights Reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?